Recommendations from a consensus development workshop on the diagnosis of fetal alcohol spectrum disorders in Australia by Watkins, Rochelle et al.
Watkins et al. BMC Pediatrics 2013, 13:156
http://www.biomedcentral.com/1471-2431/13/156RESEARCH ARTICLE Open AccessRecommendations from a consensus
development workshop on the diagnosis of fetal
alcohol spectrum disorders in Australia
Rochelle E Watkins1*, Elizabeth J Elliott2,3,4, Amanda Wilkins1,5, Raewyn C Mutch1,5, James P Fitzpatrick2,4,
Janet M Payne1, Colleen M O’Leary1,6, Heather M Jones1, Jane Latimer4, Lorian Hayes7, Jane Halliday8,
Heather D’Antoine9, Sue Miers10, Elizabeth Russell11, Lucinda Burns12, Anne McKenzie1, Elizabeth Peadon2,3,
Maureen Carter13 and Carol Bower1Abstract
Background: Fetal alcohol spectrum disorders (FASD) are underdiagnosed in Australia, and health professionals
have endorsed the need for national guidelines for diagnosis. The aim of this study was to develop consensus
recommendations for the diagnosis of FASD in Australia.
Methods: A panel of 13 health professionals, researchers, and consumer and community representatives with relevant
expertise attended a 2-day consensus development workshop to review evidence on the screening and diagnosis of
FASD obtained from a systematic literature review, a national survey of health professionals and community group
discussions. The nominal group technique and facilitated discussion were used to review the evidence on screening
and diagnosis, and to develop consensus recommendations for the diagnosis of FASD in Australia.
Results: The use of population-based screening for FASD was not recommended. However, there was consensus
support for the development of standard criteria for referral for specialist diagnostic assessment. Participants developed
consensus recommendations for diagnostic categories, criteria and assessment methods, based on the adaption of
elements from both the University of Washington 4-Digit Diagnostic Code and the Canadian guidelines for FASD
diagnosis. Panel members also recommended the development of resources to: facilitate consistency in referral and
diagnostic practices, including comprehensive clinical guidelines and assessment instruments; and to support
individuals undergoing assessment and their parents or carers.
Conclusions: These consensus recommendations provide a foundation for the development of guidelines and
other resources to promote consistency in the diagnosis of FASD in Australia. Guidelines for diagnosis will require
review and evaluation in the Australian context prior to national implementation as well as periodic review to
incorporate new knowledge.
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Internationally, five different guidelines have been deve-
loped for the diagnosis of fetal alcohol syndrome (FAS)
or fetal alcohol spectrum disorders (FASD), three of which
were published by national health agencies or proposed for
national implementation in North America [1-3]. Existing
diagnostic guidelines for FASD have been developed using
a range of approaches, including evidence-based consensus
development methods [1,2] and studies of large clinical
cohorts [4,5]. Although there is not international consensus
on the diagnostic criteria for all FASD, more recent
published guidelines [1,2,5] share some features based on
concepts established in the original Institute of Medicine
(IOM) diagnostic criteria [3] and the subsequent case-
defined University of Washington (UW) 4-Digit Diagnostic
Code [4].
Considerable gaps remain in the evidence base for diag-
nosis [6], which is likely to contribute to the variation in
diagnostic practices [7] and the lack of international con-
sensus on diagnosis. There is a need to improve service
delivery and support health professionals’ capacity to diag-
nose FASD in Australia. Studies of FAS demonstrate
inconsistency in diagnostic methods and a failure to diag-
nose the disorder [8,9], as found elsewhere [10,11]. Studies
of Australian health professionals also indicate a need for
training and resources to support practice [12,13], includ-
ing locally-appropriate guidelines to improve diagnostic
consistency and capacity [14,15].
The development of clinical guidelines is most appro-
priate where the potential impact of this is high [16]. In
the context of considerable uncertainty about the diag-
nosis of FASD among Australian health professionals
[13,14] and the absence of accurate estimates of FASD
prevalence in Australia, the potential for national guide-
lines for FASD diagnosis to improve consistency in diag-
nostic practices [16,17], and identify gaps in management
and prevention provide an important motivation for the
development of national guidelines.
The use of systematic and transparent methods in the
development of guidelines is important [18,19]. In addition,
consistent with the need for a locally relevant approach to
guideline development [16], Australian health professionals
have raised concerns about adopting existing diagnostic
guidelines for FASD, and highlighted the need for evidence
of effectiveness in the local context [14]. Guideline deve-
lopment is often a qualitative process driven by the need
to integrate diverse sources of evidence and multiple
perspectives on factors that might influence guideline
effectiveness, acceptability, suitability and utility in differ-
ent clinical contexts [18-20].
The purpose of this study was to establish evidence-
based consensus recommendations to support the develop-
ment of guidelines for the diagnosis of FASD in Australia,
including assessment methods and diagnostic criteria.Methods
Recommendations on the diagnosis of FASD were deve-
loped using systematic review and evaluation of the
evidence based on the GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation)
approach [21]. Due to the limited availability of local
empirical evidence, this process predominantly involved
evaluation and adaption of existing guidelines. This was
based on the best available evidence and input from a
panel of health professionals, consumers and others
with relevant expertise. This consensus-based frame-
work for developing recommendations is consistent
with the recognised need to move beyond research
evidence in the development of clinical guidelines [20].
The selected panel was small enough to enable explor-
ation of reasons for disagreement or uncertainty, and large
enough to produce reliable recommendations [20]. Study
chief investigators (CB and EJE) purposively recruited 15
individuals with a range of relevant expertise (FASD diag-
nosis, research, education and advocacy) from 6 Australian
states and territories. The 17 panel members included pae-
diatricians, other health professionals, health researchers
and consumer and community representatives. All panel
members participated in the study design and were actively
engaged in all components of the study.
Development of consensus recommendations for the
diagnosis of FASD (Figure 1) was conducted over
22 months (August 2010 - May 2012) and included three
main stages:
i. evidence collection and preliminary evaluation,
ii. a consensus development workshop and critical
appraisal of evidence; and
iii. post-workshop documentation and review.
Evidence collection and preliminary evaluation
We conducted: i) a systematic literature review on FASD
screening and diagnosis which updated and expanded an
existing review [6] to include literature published up to
the 30th September 2010; ii) a national consultation with
health professionals using a modified Delphi process to
identify their perceptions about adopting existing guide-
lines for diagnosis and agreement with existing screening
and diagnostic criteria as described elsewhere [14,15,22];
and iii) discussions with women in the community about
their perceptions of alcohol use in pregnancy and FASD.
Findings were summarised and circulated to panel mem-
bers for critical review before the workshop.
Consensus development workshop
The nominal group technique, which is an established
method for conducting structured group meetings [23,24],
was used in combination with other informal methods to
facilitate efficient problem exploration and consensus
Update systematic literature review
Community discussions Health professional survey
Consensus development workshop
Consumer working group Diagnostic working group
Documentation and review
Final consensus recommendations 
Finalise study design
Panel selection
Teleconference
Teleconference
M
eeting
Figure 1 Study design and methods used to develop recommendations for the diagnosis of FASD in Australia.
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particularly important given the diversity of the study
panel. Workshop sessions involved evidence review,
idea generation, large and small group discussion, and
voting processes to develop consensus. Facilitated open
group discussion sessions allowed participants to dis-
cuss and debate existing evidence; consider barriers to
implementation and factors influencing local appropri-
ateness; propose and clarify recommendations; and
identify their logic and importance.
All panel members were invited to attend the 2-day
workshop in July 2011 and 13 were able to attend. All
13 workshop participants had experience in FASD
research and represented the range of expertise of the
panel. Panel members who were unable to attend the
workshop participated in the subsequent recommenda-
tion development and review processes.
Post -workshop documentation and review
A diagnostic subgroup, including six medical practitioners
(four paediatricians), met by teleconference to review the
workshop outcomes and to complete and document
recommendations. A three-member consumer subgroup
also met by teleconference to review outcomes relating to
consumer resources. All panel members then reviewed
the consensus recommendations.Analysis
Consensus agreement was defined a priori as agreement by
at least 70% of panel members. Recorded outcomes of for-
mal and informal voting processes, flip chart records and
field notes taken during open group discussions were used
to analyse workshop findings. Qualitative descriptive ana-
lysis [25] of participant contributions in open discussions,
based on identifying and categorising the underlying mean-
ing of participant statements [26], was used to describe the
main discussion content. To support the trustworthiness
(credibility, dependability and confirmability) of the find-
ings, all participants reviewed the workshop methods and
findings to confirm that the recommendations were intern-
ally coherent and supported by the data [27].
The GRADE approach [21], which acknowledges the
influence of a range of factors on the formulation of
recommendations, was used to describe the strength
[28,29] and quality of the evidence base [29] for each
recommendation. A strong recommendation was made
when the panel concluded there was clear evidence of
balance between the desirable and undesirable effects of
the strategy, or when there was little uncertainty about the
benefits and harms of the strategy. A conditional recom-
mendation was made where there was less certainty about
the balance between desirable and undesirable effects.
Strong recommendations were unlikely to be made in the
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Evidence quality was rated high, moderate, low or very
low based on its directness, likelihood of bias, consistency
of findings, and likelihood that further research would
modify confidence in the estimated effect [30]. This study
was approved by the University of Western Australia
Human Research Ethics Committee and the Western
Australian Aboriginal Health Information and Ethics
Committee. Written informed consent for participation
was obtained from all panel members.
Results
The panel noted the lack of specific, high quality, and
locally relevant evidence on which to base recommenda-
tions about the diagnosis of FASD in Australia. Two
consensus recommendations were developed on scree-
ning and referral, and five on diagnosis (Table 1).
Screening and referral
We do not recommend population-based screening for FASD
(GRADE: strong recommendation | low quality evidence)
There are no reliable estimates of the population preva-
lence of FASD in most countries, including Australia.
There is some evidence to suggest that the prevalence of
FASD in high income countries may be as high as 2-5%
[31]. However, effective screening for FASD requires a
suitable screening test. Systematic reviews from Canada
and New Zealand found limited information on the vali-
dity on different screening tests for FASD, insufficient
evidence to justify population-based screening, and no
single screening method for FASD suitable for all popu-
lations [6,32]. Similarly, our survey findings indicate little
support for population-based screening, and highlight
the absence of evidence on effectiveness [15]. Survey
respondents and workshop participants also identifiedTable 1 Summary of consensus recommendations for the dia
Area Recommendation
Population screening We do not recommend population-based scree
Referral We recommend the use of standard criteria for
recommendation | low quality evidence)
Diagnostic categories We recommend the diagnostic categories of fetal
disorder-alcohol exposed for use in Australia (GRA
Diagnostic criteria We recommended that the diagnosis of fetal a
disorder-alcohol exposed are based on the crite
quality evidence)
Diagnostic assessment
methods
We recommend standard diagnostic assessmen
assessment (GRADE: conditional recommendati
Resources for
implementation
We recommend the development of comprehe
diagnostic criteria and national case reporting (
Consumer information
and support
We recommend that information and support
diagnostic process (GRADE: conditional recomm
FASD – fetal alcohol spectrum disorders;
GRADE – Grading of Recommendations Assessment, Development and Evaluation [that the capacity for diagnosing and managing FASD in
Australia is currently inadequate to support the intro-
duction of population-based screening, and that in this
context the harms of population-based screening out-
weigh its potential benefits.
There is some evidence that the benefits of screening
may be greater among individuals in foster care, correc-
tional environments and other high risk groups [33-37].
Evaluation of the feasibility, acceptability and effectiveness
of screening for FASD in high risk groups is required
before considering targeted screening in Australia.
We recommend the use of standard criteria for referral for
specialist diagnostic assessment (GRADE: conditional
recommendation | low quality evidence)
Both survey [15] and workshop participants endorsed
the need for standard referral criteria to promote
consistency and certainty in identifying the need for
specialist assessment. Existing evidence-based diagnostic
guidelines for FAS [1] and FASD [2] also recommend
standard criteria for specialist referral. Studies of clinical
cohorts [38] and high risk groups [33,39] provide evi-
dence to support the use of standard criteria to identify
the need for specialist diagnostic assessment, including
prenatal alcohol exposure, growth deficit, central ner-
vous system (CNS) dysfunction and developmental
delay. Referral criteria for Australia should be adapted
from existing consensus criteria [1,2], and evaluated in
the local context.
Our conditional recommendation reflects the lack of
direct high quality evidence of the effectiveness, costs and
benefits of specific criteria for referral, and of whether
implementation of standard referral criteria can improve
awareness among health professionals of the need to as-
sess prenatal alcohol exposure and consider FASD as agnosis of FASD in Australia
ning for FASD (GRADE: strong recommendation | low quality evidence)
referral for specialist diagnostic assessment (GRADE: conditional
alcohol syndrome, partial fetal alcohol syndrome and neurodevelopmental
DE: conditional recommendation | low quality evidence)
lcohol syndrome, partial fetal alcohol syndrome and neurodevelopmental
ria summarised in Table 2 (GRADE: conditional recommendation | low
t based on the comprehensive interdisciplinary UW approach to
on | low quality evidence)
nsive resources to facilitate national implementation of standard
GRADE: conditional recommendation | low quality evidence)
are provided for individuals and their parents or carers during the
endation | low quality evidence)
21].
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high value on early diagnosis [40] and the demon-
strated need for improved awareness among health
professionals [8,12,13].
Diagnosis
There is evidence that making a diagnosis of FASD, in
combination with appropriate maternal services and sup-
port, can prevent the subsequent birth of affected children
[35,41], reduce inappropriate management which may be
harmful or counterproductive in individuals with FASD
[42-44], and enable access to interventions that provide
sustained benefit for affected individuals, their families
and communities [40,45,46]. Workshop participants pro-
posed that the diagnostic criteria used in either the UW
[4] or Canadian [2] guidelines, or a combination of the
two, should be used as a basis for the diagnosis of FASD
in Australia. After reviewing the evidence, a formal vote
established consensus support for combining elements of
the UW and Canadian guidelines. Below are listed the five
key recommendations for diagnosis in Australia.
We recommend the diagnostic categories of FAS, PFAS and
neurodevelopmental disorder-alcohol exposed (ND-AE) for
use in Australia (GRADE: conditional recommendation | low
quality evidence)
The diagnostic categories recommended for use in
Australia are FAS, PFAS and ND-AE. Despite the lack of
established agreed diagnostic categories, FAS, PFAS, and
alcohol-related neurodevelopmental disorder (ARND)
are consistently identified as categories within the FASD
spectrum [2-5,47-52]. The Australian category ND-AE
reflects severe CNS dysfunction in the absence of facial
anomalies and is broadly equivalent to the Canadian cat-
egory ARND and the UW category static encephalopathy-
alcohol exposed (SE-AE). Consistent with the Canadian
guidelines, we do not recommend use of the UW diag-
nostic category of neurobehavioural disorder-alcohol
exposed at this time, which requires evidence of moderate
as opposed to severe CNS dysfunction. Although there is
an extensive evidence base confirming prenatal alcohol
exposure causes the full range of outcomes from moderate
to severe CNS dysfunction [38,50-53] and a growing
evidence base documenting significant CNS structural
abnormalities among alcohol-exposed individuals with mod-
erate dysfunction [38,47]; panel members identified the need
for additional evidence to more fully evaluate the validity of
diagnosis based on moderate CNS dysfunction, including
significant dysfunction in only two domains or evidence of
less severe dysfunction in three or more domains.
There was consensus that the diagnostic terminology
for ARND should be modified to ensure that it describes
the nature of the impairment, is meaningful to clinicians
and consumers, and reflects the potentially unknown andmultifactorial origins of neurodevelopmental disorders.
The diagnostic term ND-AE uses the UW convention of
designating a diagnostic category as alcohol exposed,
rather than alcohol-related. Consistent with the UW and
Canadian Guidelines, and evidence from the systematic
review [6,54], the diagnostic category alcohol-related birth
defects (ARBD) was not recommended for use.
We recommended that the diagnosis of FAS, PFAS and ND-AE
are based on the criteria summarised in Table 2 (GRADE:
conditional recommendation | low quality evidence)
There is a growing evidence base for the UW diagnostic
criteria [38,47,48,55-60], and there has been little valid-
ation of the Canadian criteria. However, participants
recognised that there are a number of similarities between
the UW and Canadian criteria for the diagnostic categor-
ies of FAS, PFAS and SE-AE/ARND (ND-AE). There was
consensus agreement that the diagnostic criteria should
include elements from both the UW and Canadian guide-
lines as outlined in Table 2, and that this would facilitate
standardised reporting of diagnoses nationally.
Panel members identified a lack of evidence to compare
the performance of criteria for CNS abnormality from the
UW and Canadian guidelines, and that the specific criteria
for establishing severe CNS damage or dysfunction was
the greatest area of uncertainty in diagnosis, particularly in
the absence of characteristic facial anomalies. Specifically,
there was uncertainty about whether microcephaly alone
was sufficient to indicate CNS damage, and whether mod-
erate dysfunction was sufficient to indicate CNS damage.
Consistent with the survey findings [22], use of the UW
criteria for CNS abnormality, based on a significant struc-
tural abnormality or significant dysfunction in three or
more domains, was recommended.
The requirement for confirmed prenatal alcohol expos-
ure for the diagnosis of ARND or SE-AE in the Canadian
and UW guidelines respectively was also recommended
for the diagnosis of ND-AE. The panel acknowledged dif-
ficulties in the quantification of prenatal alcohol expos-
ure associated with the availability of information on
specific levels of exposure; variation in individual sus-
ceptibility; and implications for the interpretation of a
safe level of exposure. Due to the range of factors that
may modify the effect of prenatal alcohol exposure on
growth [61-63], the diagnostic criteria for PFAS do not
require the presence of a growth deficit, consistent with
the UW and Canadian guidelines.
We recommend standard diagnostic assessment based on the
comprehensive interdisciplinary UW approach to assessment
(GRADE: conditional recommendation | low quality evidence)
To facilitate the use of valid and comprehensive assess-
ment methods, workshop participants recommended the
development of standard assessment protocols for all
Table 2 Recommended Australian FASD diagnostic categories and criteria
Diagnostic
criteria#
Diagnostic category
Fetal Alcohol Syndrome (FAS) Partial Fetal Alcohol Syndrome (PFAS) Neurodevelopmental
Disorder-Alcohol
Exposed (ND-AE)
Requirements
for diagnosis
Requires all 4 of the following criteria to be met: Requires confirmed prenatal alcohol exposure, the
presence of 2 of the 3 characteristic FAS facial
anomalies at any age, and CNS criteria to be met:
Requires confirmed
prenatal alcohol exposure
and CNS criteria to be met:
Prenatal alcohol
exposure
Confirmed or unknown Confirmed Confirmed
Facial anomalies Simultaneous presentation of all 3 of the following
facial anomalies at any age:
Simultaneous presentation of any 2 of the
following facial anomalies¤ at any age:
No anomalies required*
i. short palpebral fissure length (2 or more
standard deviations below the mean)
i. short palpebral fissure length (2 or more
standard deviations below the mean)
ii. smooth philtrum (Rank 4 or 5 on the UW
Lip-Philtrum Guide†)
ii. smooth philtrum (Rank 4 or 5 on the UW
Lip-Philtrum Guide†)
iii. thin upper lip (Rank 4 or 5 on the UW
Lip-Philtrum Guide†)
iii. thin upper lip (Rank 4 or 5 on the UW
Lip-Philtrum Guide†)
Growth deficit Prenatal or postnatal growth deficit indicated by
birth length or weight≤ 10th percentile adjusted
for gestational age, or postnatal height or
weight≤ 10th percentile
No deficit required* No deficit required*
Central Nervous
System (CNS)
abnormality
At least 1 of the following:
i. clinically significant structural abnormality (e.g. OFC≤ 3rd percentile, abnormal brain structure), or neurological abnormality
(seizure disorder or hard neurological signs); and/or
ii. severe dysfunction (impairment in 3 or more domains of function, 2 or more standard deviations below the mean) ‡
OFC-occipital-frontal circumference. †University of Washington Lip-Philtrum Guides: http://depts.washington.edu/fasdpn/htmls/lip-philtrum-guides.htm.
*Not required for diagnosis but may be present. #Appropriate reference charts should be used, and other causes of growth deficit and CNS abnormality excluded.
‡Assessment of dysfunction based on evidence from standard validated assessment instruments interpreted by qualified professionals.
¤Based on the presence of 2 of the 3 characteristic FAS facial features, the observed impairments cannot be causally linked to prenatal alcohol exposure.
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interdisciplinary approach to diagnostic assessment, as also
recommended in the Canadian guidelines. The UW diag-
nostic assessment approach was recommended based
on its use of specific, quantifiable assessment methods,
the accumulated evidence base resulting from its use
[38,47,48,55,56], and endorsement of these methods by
health professionals [14,22]. Panel members reached
consensus agreement on essential components of the diag-
nostic assessment as listed in Table 3, all of which are
assessed in the UW 4-Digit Diagnostic Code approach [4].
Given the lack of resources for specialised diagnostic
services for FASD in Australia, a multidisciplinary ap-
proach to diagnosis with coordinated contributions
from a range of professionals was considered more
feasible for national implementation in the short term
than the ideal interdisciplinary assessment model,
where professionals from different disciplines work
together in a structured and integrated team approach
to diagnosis. The panel recommended that diagnostic
assessment findings be directly applied to the identifi-
cation of relevant diagnostic outcomes based on the
Australian diagnostic criteria, and that the UW 4-digit
code could also be derived if desired.Consistent with nationally endorsed methods for the
assessment of alcohol intake during pregnancy [64],
panel members recommended standard assessment of
prenatal alcohol exposure using the AUDIT-C [65]. This
should be administered in combination with a clinical
interview and case note review, where relevant, to obtain
additional information about consumption patterns and
timing. Both survey [14] and workshop participants
noted a lack of evidence on which to evaluate the appro-
priateness of existing population references for the
assessment of growth, facial anomalies and neurocognitive
function, and the need for studies to determine culturally
appropriate references for use in Australia.
We recommend the development of comprehensive
resources to facilitate national implementation of standard
diagnostic practices and national case reporting (GRADE:
conditional recommendation | low quality evidence)
A comprehensive implementation plan was recommended
to facilitate national adoption of standard diagnostic prac-
tices and development of systems for national surveillance
of FASD. The implementation plan should include
strategies and resources to: improve health professionals’
awareness of national diagnostic guidelines for FASD;
Table 3 Recommended Australian FASD diagnostic
assessment content
Recommended content Content included on the UW FASD
Diagnostic Form or New Patient
Information Form
History: Yes
Family/social Yes
Prenatal medical Yes
Obstetric Yes
Neonatal Yes
Developmental Yes
Academic Yes
Current problems Yes
Pre + post natal alcohol +
other prenatal exposures
Yes
Paternal drinking Yes
Drug and alcohol use in the
child or individual
Yes
Early life trauma Yes
Examination: Yes
Growth Yes
Head circumference Yes
Dysmorphology Yes
Central nervous system Yes
Birth defects Yes
Medical investigations Yes
Diagnostic criteria Yes
Exclusion of other diagnoses Yes
Reporting final diagnosis
by category
Yes
Results summary: strengths
and areas of need
Yes
Follow-up and management plan Yes
UW-University of Washington 4-Digit Diagnostic Code [4].
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training and support for health professionals, and establish
national mechanisms for reporting and surveillance. Re-
sources required would include comprehensive guidelines
for diagnosis, standard instruments for referral and diag-
nosis, and training resources for health professionals.
We recommend that information and support are provided
for individuals and their parents or carers during the
diagnostic process (GRADE: conditional recommendation |
low quality evidence)
Panel members recommended that culturally appropriate
information and support services including counselling and
advocacy should be available for individuals undergoing
diagnostic assessment and their parents or carers. These
should inform parents and carers or individuals about thediagnostic and management process and goals prior to the
assessment, and provide on-going support. This recom-
mendation recognises the importance of acknowledging the
values and preferences of individuals undergoing assess-
ment in clinical decision-making. Informed consent
should be obtained and recorded prior to conducting
the diagnostic assessment and communicating diagnos-
tic findings to other individuals or external organisa-
tions. We recommend that parents and carers are
involved in evaluating FASD resources and services as a
part of standard quality improvement processes.
Discussion
We propose evidence-based consensus recommendations
for the diagnosis of FASD in Australia based on adaption
of elements from the UW and Canadian guidelines. These
recommendations were based on a review of evidence
from published research and input from individuals with
relevant expertise, including health professionals and con-
sumer and community representatives. We recommend
the three well established diagnostic categories of FAS,
PFAS and ND-AE for use in Australia. The construct
validity of the endorsed diagnostic categories is supported
by the adoption of these categories in all published diag-
nostic guidelines for FASD internationally [2-5], despite
minor differences in diagnostic criteria. However, there is
not universal support for the validity of the diagnostic
category of ND-AE/ARND or for the diagnosis of PFAS
based on the presence of only two characteristic facial
anomalies, and we acknowledge that the three diagnostic
categories recommended for use do not represent the
complete spectrum of disorders associated with prenatal
alcohol exposure. The adequacy of evidence for diagnosis
in these areas is still subject to debate.
Our systematic review of the literature demonstrated a
lack of agreed diagnostic criteria for FASD and a lack of
high quality evidence to enable direct comparison of dif-
ferent diagnostic criteria or evaluate their local applicabil-
ity. These factors limited the use of the GRADE approach
in developing recommendations, and our frequent use of
conditional recommendations reflects uncertainty associ-
ated with current evidence base for diagnosis. Uncertainty
was most notable for the Australian diagnostic criteria for
ND-AE, where consensus was to use diagnostic criteria
comparable with the UW guidelines for SE-AE and the
Canadian guidelines for ARND in the requirement for
evidence of severe CNS dysfunction, which is a more con-
servative approach than recommended in other guidelines
[4,5]. Recommendations for Australia differ from the UW
and Canadian guidelines in the lack of need to derive the
4-digit code; however, it can be derived if required.
Due to the lack of gold standard criteria for the diagnosis
of FASD and categories within the spectrum, guideline
development relied on a consensus-based approach.
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include the potential for bias in the recruitment of panel
members and in the participation of panel members in rec-
ommendation development. We attempted to minimise
this bias by recruiting panel members from different states
and territories and a range of professional backgrounds, use
of an experienced facilitator, and use of formal consensus-
development methods and structured group interaction to
promote the involvement of all panel members.
The development of these recommendations was based
on an integrated program of evidence collection and eva-
luation which aimed to facilitate extended engagement in
a comprehensive critical evaluation process, used multiple
sources of evidence, and consulted with health pro-
fessionals and consumers to ensure recommendations
were acceptable and locally appropriate. These processes
allowed identification of uncertainty and reasons for dis-
agreement, and provided a strong foundation for the con-
tent validity of these consensus-based recommendations.
National guidelines for diagnosis will require review and
evaluation to establish their appropriateness and feasibility
in the Australian context. This includes review by health
professionals, policymakers, consumers and other stake-
holders to identify issues that may affect performance,
acceptability, cost-effectiveness and implementation [66].
The development of a comprehensive national implementa-
tion strategy, including specific resources to support imple-
mentation, is also required to facilitate adoption of national
guidelines, improve diagnostic capacity and enhance the
evidence base for diagnosis, surveillance, prevention, and
management.
Conclusion
National guidelines are required to promote consistent
diagnostic practices for FASD in Australia and improve
diagnostic capacity. These workshop recommendations
provide a consensus-based foundation for the develop-
ment of guidelines adapted from the UW and Canadian
guidelines. Guidelines for diagnosis will require review
and evaluation in the Australian context prior to national
implementation as well as periodic review to incorporate
new knowledge.
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